PL2609916T3 - Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń - Google Patents

Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń

Info

Publication number
PL2609916T3
PL2609916T3 PL12196650T PL12196650T PL2609916T3 PL 2609916 T3 PL2609916 T3 PL 2609916T3 PL 12196650 T PL12196650 T PL 12196650T PL 12196650 T PL12196650 T PL 12196650T PL 2609916 T3 PL2609916 T3 PL 2609916T3
Authority
PL
Poland
Prior art keywords
related disorders
new therapeutic
therapeutic approaches
treating cmt
cmt
Prior art date
Application number
PL12196650T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Oxana Guerassimenko
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of PL2609916T3 publication Critical patent/PL2609916T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL12196650T 2007-11-30 2008-11-28 Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń PL2609916T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03
PCT/EP2008/066468 WO2009068668A1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating cmt and related disorders
EP08854467A EP2211846B1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating CMT and related disorders
EP12196650.1A EP2609916B1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating CMT and related disorders

Publications (1)

Publication Number Publication Date
PL2609916T3 true PL2609916T3 (pl) 2019-03-29

Family

ID=39264515

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08854467T PL2211846T3 (pl) 2007-11-30 2008-11-28 Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń
PL12196650T PL2609916T3 (pl) 2007-11-30 2008-11-28 Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08854467T PL2211846T3 (pl) 2007-11-30 2008-11-28 Nowe podejścia terapeutyczne do leczenia CMT i pokrewnych zaburzeń

Country Status (24)

Country Link
US (6) US8992891B2 (pl)
EP (4) EP2065038A1 (pl)
JP (4) JP5953000B2 (pl)
KR (1) KR101546031B1 (pl)
CN (2) CN104257657B (pl)
AU (1) AU2008328745B2 (pl)
BR (1) BRPI0819678A2 (pl)
CA (3) CA3031490C (pl)
CY (2) CY1113980T1 (pl)
DK (2) DK2609916T3 (pl)
EA (3) EA032767B1 (pl)
ES (3) ES2831855T3 (pl)
HR (2) HRP20130345T1 (pl)
HU (1) HUE040596T2 (pl)
IL (1) IL205741A0 (pl)
LT (1) LT2609916T (pl)
MX (1) MX2010005709A (pl)
NZ (1) NZ585440A (pl)
PL (2) PL2211846T3 (pl)
PT (2) PT2211846E (pl)
SI (2) SI2609916T1 (pl)
TR (1) TR201819564T4 (pl)
WO (1) WO2009068668A1 (pl)
ZA (1) ZA201003610B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
WO2010025322A2 (en) * 2008-08-28 2010-03-04 The Florida International University Board Of Trustees Magnetic nanodelivery of therapeutic agents across the blood brain barrier
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US9494605B2 (en) * 2009-11-20 2016-11-15 Pharnext Diagnostic tools for charcot-marie-tooth disease
LT2523661T (lt) 2010-01-15 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Nkcc inhibitoriai autizmo gydymui
ES2647368T3 (es) * 2010-10-08 2017-12-21 Vib Vzw Inhibidores de HDAC para tratar la enfermedad de Charcot-Marie-Tooth
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
EP3502236B1 (en) 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
ES2702848T3 (es) 2011-02-23 2019-03-05 Coeruleus Ltd Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
WO2014063163A1 (en) 2012-10-19 2014-04-24 Block Jonathan D Systems and methods for nerve mapping and monitoring
EP2931267A1 (en) * 2012-12-17 2015-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
DK3003268T3 (en) 2013-06-05 2018-11-05 Pharnext STABLE ORAL SOLUTIONS FOR COMBINED API
MX2016010409A (es) 2014-02-11 2016-11-30 Pharnext Combinacion de baclofeno, acamprosato y trigliceridos de cadena media para el tratamiento de trastornos neurologicos.
MX373808B (es) * 2014-02-24 2020-03-24 Pharnext Nuevas composiciones para tratar lesiones neuronales mecánicas.
WO2016187595A2 (en) * 2015-05-20 2016-11-24 Lupin Atlantis Holdings Sa Oral pharmaceutical composition of methylergonovine
WO2017156242A1 (en) * 2016-03-09 2017-09-14 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting pmp22 expression
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US11272871B2 (en) 2016-07-14 2022-03-15 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
AU2017351638A1 (en) * 2016-10-26 2019-06-13 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
JP2022531466A (ja) * 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
WO2021222165A1 (en) * 2020-05-01 2021-11-04 Applied Therapeutics, Inc. Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
US20250154135A1 (en) * 2022-01-29 2025-05-15 Nanjing Gritpharma Co., Ltd. M-choline receptor agonist compound, preparation method therefor and use thereof
EP4497437A4 (en) * 2022-03-22 2025-03-12 Kyoto University MEDICINES FOR THE TREATMENT OR PREVENTION OF CHARCOT-MARIE-TOOTH DISEASE

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
RU2184570C2 (ru) 1997-09-30 2002-07-10 Дайити Фармасьютикал Ко., Лтд. Препараты для орального введения
EP1117425A2 (en) * 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
JP2004504002A (ja) * 1999-01-19 2004-02-12 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトシャペロンタンパク質
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
RU2325152C2 (ru) * 2001-07-04 2008-05-27 Сан Фармасьютикл Индастриз Лимитид Удерживаемая в желудке система регулируемой доставки лекарственного средства
KR20040098660A (ko) * 2002-03-14 2004-11-20 유로-셀티크 소시에떼 아노뉨 날트렉손 하이드로클로라이드 조성물
DK1578350T3 (da) * 2002-03-26 2009-08-10 Euro Celtique Sa Sammensætninger med gel-coating med depotvirkning
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
CA2495917A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
EP2343045A3 (en) * 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Transmucosal drug delivery system
CA2811272C (en) * 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
EP1613324A2 (en) * 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
MXPA06003392A (es) 2003-09-25 2006-06-08 Euro Celtique Sa Combinacion farmaceutica de hidrocodona y naltrexona.
JP4994039B2 (ja) 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2382975A3 (en) * 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
TWI369982B (en) 2007-01-11 2012-08-11 Xenoport Inc Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
KR101937782B1 (ko) 2011-03-01 2019-01-11 파넥스트 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
DK3003268T3 (en) 2013-06-05 2018-11-05 Pharnext STABLE ORAL SOLUTIONS FOR COMBINED API
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
JP2011504915A (ja) 2011-02-17
TR201819564T4 (tr) 2019-01-21
IL205741A0 (en) 2010-11-30
PL2211846T3 (pl) 2013-09-30
SI2609916T1 (sl) 2019-03-29
HRP20130345T1 (hr) 2013-07-31
PT2609916T (pt) 2019-01-10
PT2211846E (pt) 2013-05-10
CN104257657B (zh) 2017-07-04
EA201301078A1 (ru) 2014-06-30
CA3031490C (en) 2021-05-04
ES2703508T3 (es) 2019-03-11
JP2019142917A (ja) 2019-08-29
ES2831855T3 (es) 2021-06-09
JP2018109043A (ja) 2018-07-12
US10441558B2 (en) 2019-10-15
US20180338969A1 (en) 2018-11-29
EP2211846A1 (en) 2010-08-04
US10322101B2 (en) 2019-06-18
CN101883561A (zh) 2010-11-10
JP2016145227A (ja) 2016-08-12
CA2705408C (en) 2019-04-23
JP5953000B2 (ja) 2016-07-13
WO2009068668A1 (en) 2009-06-04
EA201791669A2 (ru) 2017-12-29
US20200155491A1 (en) 2020-05-21
HRP20182147T8 (hr) 2019-04-19
US10463640B2 (en) 2019-11-05
DK2609916T3 (en) 2019-01-21
EP3459535B1 (en) 2020-08-12
EP2065038A1 (en) 2009-06-03
CY1121183T1 (el) 2020-05-29
EP2609916A1 (en) 2013-07-03
EP2211846B1 (en) 2013-02-27
KR20100088160A (ko) 2010-08-06
CA3031484A1 (en) 2009-06-04
LT2609916T (lt) 2019-02-11
CA3031490A1 (en) 2009-06-04
ZA201003610B (en) 2011-06-29
US8992891B2 (en) 2015-03-31
EA201000914A1 (ru) 2010-12-30
US20180360785A1 (en) 2018-12-20
CN104257657A (zh) 2015-01-07
CN101883561B (zh) 2014-07-30
JP6608309B2 (ja) 2019-11-20
DK2211846T3 (da) 2013-04-29
KR101546031B1 (ko) 2015-08-25
AU2008328745B2 (en) 2014-01-30
AU2008328745A1 (en) 2009-06-04
HRP20182147T1 (hr) 2019-03-08
ES2408785T3 (es) 2013-06-21
EP3459535A1 (en) 2019-03-27
EP2609916B1 (en) 2018-11-07
CA2705408A1 (en) 2009-06-04
SI2211846T1 (sl) 2013-07-31
EA032767B1 (ru) 2019-07-31
CY1113980T1 (el) 2016-07-27
HUE040596T2 (hu) 2019-03-28
MX2010005709A (es) 2010-11-05
US20180250289A1 (en) 2018-09-06
EA019402B1 (ru) 2014-03-31
NZ585440A (en) 2011-12-22
BRPI0819678A2 (pt) 2017-05-09
US20150157626A1 (en) 2015-06-11
EA201791669A3 (ru) 2018-03-30
US20100310641A1 (en) 2010-12-09
EA035711B1 (ru) 2020-07-29
CA3031484C (en) 2021-05-04

Similar Documents

Publication Publication Date Title
HRP20182147T8 (hr) Novi terapijski pristupi za liječenje cmt-a i srodnih poremećaja
ZA201003497B (en) Methods for treating obesity and obesity related diseases and disorders
ZA200900734B (en) Combination treatment for metabolic disorders
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
GB0918546D0 (en) Compounds for treating ophthalmic diseases and disorders
GB0602178D0 (en) Therapeutic treatment
IL209216A0 (en) Methods for preventing and treating neurodegenerative diseases
IL222557A (en) A compound for use in treating mutant disorders has ruled
ZA201109423B (en) New compositions for treating cmt and related disorders
EP2219448A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
IL201422A0 (en) Therapeutic agents useful for treating pain
ZA201002167B (en) Treatment regime for proliferative disorders
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
IL218321A0 (en) Therapeutic agent for mood disorders
GB0608655D0 (en) Therapeutic Treatment
PT2481407T (pt) Compostos para utilização no tratamento de distúrbios cognitivos
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
GB0702537D0 (en) Treatment for excessive adiposity
GB0610909D0 (en) Therapeutic treatment
IL207906A0 (en) Treatment for ocular-related disorders
SI2278962T1 (sl) Postopki za zdravljenje dermatoloških motenj
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
GB0610376D0 (en) Therapeutic treatment
ZA200905750B (en) Therapeutic agents useful for treating pain
GB0711403D0 (en) Therapy for immune disorders